｜Edited by the Content Team of Zhong肽 BiochemicalDecember 13, 2023The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2023)" (hereinafter referred to as the "National Medical Insurance Catalog"). Two indications of Hansoh Pharma's self-developed Class 1 innovative drug, Serolibe® (Pegmoceptin Injection), have been successfully included in the medical insurance. Another innovative drug, Hengmu® (Amytenofovir Tablets) has also been successfully renewed. The new version of the National Medical Insurance Catalog will be officially implemented on January 1, 2024. Thus far, all seven innovative drugs launched by Hansoh Pharma have been included in the National Medical Insurance Catalog.
Santurol® is the world's only approved EPO mimetic peptide, modified by third-generation branched polyethylene glycol, significantly extending its half-life. It contains no free lysine residues, thus carbamylation cannot occur. With high affinity, it requires only once every 4 weeks subcutaneous injection to help patients achieve stable target levels, demonstrating good safety. Santurol® will provide patients with a new option for long-acting, stable, enduring, and safe treatment. Santurol® fills the gap in China for monthly formulations in the treatment of renal anemia, and is expected to usher in a new chapter in the long-term management of renal anemia.
About Sinrolin®
Sarlorel® (Pemodapeptide Injection) is the "world's only approved EPO mimetic peptide" independently developed by Hansoh Pharma. It was approved for marketing by the National Medical Products Administration (NMPA) in June 2023. It is indicated for the treatment of anemia caused by chronic kidney disease (CKD), including adult non-dialysis patients not receiving erythropoiesis-stimulating agent (ESA) therapy and adult dialysis patients receiving short-acting erythropoietin (EPO) therapy (this product is not suitable as a substitute for red blood cell transfusion in patients requiring immediate correction of anemia).SinoRel® is the seventh innovative drug approved for marketing by Hansoh Pharma, and also the first innovative drug of Hansohn Pharma to be simultaneously approved for two indications.Renal Anemia is One of the Most Common Complications of CKD. Epidemiological data show that the prevalence rate of CKD among Chinese adults is 10.8%, with more than 50% also suffering from anemia. As CKD progresses, the prevalence of renal anemia increases continuously. The overall prevalence of anemia in non-dialysis CKD patients ranges from 28.5% to 72.0%, while in dialysis patients, the prevalence of anemia is as high as 91.6%-98.2%. Anemia not only affects the quality of life of patients with kidney disease but also promotes the progression of kidney disease and increases the risk of end-stage renal disease, cardiovascular events, and mortality.
Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with subsidiaries including Hansoh Pharmaceuticals, Changzhou Hengbang Pharmaceuticals, and Hansoh Biologics. The company focuses on major disease treatment areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmune diseases, and is committed to improving the quality of human life through continuous innovation. To date, the company has launched seven innovative drugs, with revenue from innovative drugs accounting for 61.8% of its total revenue. Hansoh Pharma has consistently ranked among the top 100 global pharmaceutical companies and has been among the top three in China's Best Industrial Pharmaceutical R&D Product Lines for many years. It is a key national high-tech enterprise and a national technology innovation demonstration enterprise.1.Good News | Hansoh Pharma's Rocyle® Included in China's National Medical Insurance Catalogue, Opening a New Chapter in Long-Acting Management of CKD-Related Anemia in China - News Release - Hansoh Pharmaceutical Group Company Limited (hspharm.com)
